← European Medicine Shortage Tracker · all medicines
Availability information only — Mobi Doctor doesn't sell medicines; check with a pharmacy.
Tétracosactide currently has availability issues reported in 1 European register: Greece.
Limited availability ATC H01AA02 · also listed as: tétracosactide · Tetracosactide · data refreshed 11 September 2026
As of 11 September 2026, 1 of the 9 tracked registers list current availability issues for Tétracosactide, covering 1 affected product presentation. The longest-running open report was filed in Greece on 2026-07-03 and has now been open for about 2 months. The furthest expected-resolution date currently on file is 2026-10-30; the earliest is 2026-10-30. Registers in Greece indicate that alternatives or equivalents are available — a pharmacist or doctor can advise on switching. In the WHO ATC classification, Tétracosactide is coded H01AA02 — a medicine acting on systemic hormonal preparations — so clinically related products appear under “Related medicines” below.
| Where | Status & products | Since | Expected end | Reason / alternatives | Source |
|---|---|---|---|---|---|
| 🇫🇷 France | Resolved Synacthène 0,25 mg/1 ml, solution injectable | — | 2026-07-22 | Endocrinologie, Neurologie | register ↗ |
| 🇬🇷 Greece | Limited availability Tetracosactide | 2026-07-03 | 2026-10-30 | Ν+Φ Ι.Φ.Ε.Τ. ΔΙΑΔΙΚΑΣΙΑ ΜΕΤΑΒΙΒΑΣΗΣ Alternatives: ΤΗΣ ΑΔΕΙΑΣ ΣΕ ΑΛΛΟΝ ΚΑΚ | register ↗ |
Every individual register entry for Tétracosactide in the tracked sources, newest first — including resolved and discontinued reports.
| Reg. | Product | Status | Reported | Expected end | Stated reason |
|---|---|---|---|---|---|
| 🇬🇷 GR | Tetracosactide | Limited availability | 2026-07-03 | 2026-10-30 | Ν+Φ Ι.Φ.Ε.Τ. ΔΙΑΔΙΚΑΣΙΑ ΜΕΤΑΒΙΒΑΣΗΣ |
| 🇫🇷 FR | Synacthène 0,25 mg/1 ml, solution injectable | Resolved | — | 2026-07-22 | Endocrinologie, Neurologie |
Yes. As of 11 September 2026, availability issues are reported in: Greece. Availability is national — a shortage in one country does not mean it is short everywhere.
Agency prognoses on file range from 2026-10-30 to 2026-10-30. These are manufacturer-reported estimates and frequently move; check the linked register entry for the latest date.
1 of the active register entries indicate alternatives or equivalents (same active substance or an alternative treatment). Do not switch on your own — a pharmacist or prescriber can confirm the right substitute in your country.
Directly from the official medicines-agency registers that list Tétracosactide: ANSM (France), EOF limited-availability list (Greece). Every row on this page links to the underlying official record, and the dataset is refreshed from the primary sources every morning. Cross-language matching groups the same active substance across registers, so national spellings all resolve to this page.
Pharmacies, patient sites and newsrooms are welcome to embed the live status of Tétracosactide — free, with attribution. Copy this snippet:
<iframe src="https://www.mobidoctor.eu/medicine-shortages/medicine-shortages/tetracosactide/embed.html" width="100%" height="150" loading="lazy" style="border:1px solid #e1e0d9;border-radius:12px" title="Tétracosactide availability in Europe"></iframe> <p style="font-size:12px">Source: <a href="https://www.mobidoctor.eu/medicine-shortages/medicine-shortages/tetracosactide/">Tétracosactide shortage status — European Medicine Shortage Tracker</a> by MobiDoctor</p>